Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.48 |
| ▸ | TUBB | P07437 | 2/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390059 | 0.89 | LMNA (0.68) | SMN1; SMN2LMNATSHREPHX2KCNH2 | |
| SCHEMBL386041 | 0.86 | SMN1; SMN2 (0.63) | SMN1; SMN2LMNATSHREPHX2KCNH2 | |
| SCHEMBL389460 | 0.85 | LMNA (0.62) | SMN1; SMN2LMNATSHREPHX2KCNH2 | |
| SCHEMBL389835 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNATSHREPHX2KCNH2 | |
| SCHEMBL389836 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNATSHREPHX2KCNH2 | |
| SCHEMBL388852 | 0.82 | GPR119 (0.73) | SMN1; SMN2LMNATSHRKCNH2HTT | |
| SCHEMBL390646 | 0.82 | GPR119 (0.67) | SMN1; SMN2LMNATSHREPHX2KCNH2 | |
| SCHEMBL4513166 | 0.80 | SMN1; SMN2 (0.73) | SMN1; SMN2LMNATSHREPHX2KCNH2 | |
| SCHEMBL390887 | 0.78 | LMNA (0.67) | SMN1; SMN2LMNATSHREPHX2KCNH2 | |
| SCHEMBL389766 | 0.76 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNATSHREPHX2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207147-B2 | Heterocyclic derivatives as GPCR receptor agonists | PROSIDION LIMITED (GB) | 2012-06-26 | — | — | US | claimed |
| EP-1758565-B2 | Method of identifying GLP-1 secretagogues | ARENA PHARM INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-8207147-B2 | Heterocyclic derivatives as GPCR receptor agonists | PROSIDION LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207147-B2 | Heterocyclic derivatives as GPCR receptor agonists | PROSIDION LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207147-B2 | Heterocyclic derivatives as GPCR receptor agonists | PROSIDION LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8198232-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8030270-B2 | Methods for identifying GLP-1 secretagogues | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8022034-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8003597-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-1758565-B1 | Method of identifying GLP-1 secretagogues | ARENA PHARM INC (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-1997484-A2 | Method of identifying GLP-1 secretagogues | Arena Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1808168-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| EP-1758565-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | Arena Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006076231-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | SMN1; SMN2 3911/4885LMNA 4082/4885TSHR 479/4885 |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | SMN1; SMN2 3911/4885LMNA 4082/4885TSHR 479/4885 |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | SMN1; SMN2 3911/4885LMNA 4082/4885TSHR 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.